Clinical significance of Clara cell secreted protein 16 and pulmonary surfactant protein-A in early diagnosis of neonatal acute respiratory distress syndrome
10.3760/cma.j.issn.1673-4912.2021.08.012
- VernacularTitle:血清Clara细胞分泌蛋白16及肺表面活性蛋白A在新生儿急性呼吸窘迫综合征诊断中的临床意义
- Author:
Lu CHEN
1
;
Jiakai WEI
;
Yao AN
;
Jie ZHANG
;
Yujuan ZHAO
Author Information
1. 西安交通大学附属西安市儿童医院新生儿科 710003
- Keywords:
Acute respiratory distress syndrome;
Clara cell secretory protein 16;
Pulmonary surfactant protein-A;
Infant, neonatal
- From:
Chinese Pediatric Emergency Medicine
2021;28(8):697-700
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical significance of changes of serum Clara cell secretory protein(CC16) and pulmonary surfactant protein A(SP-A) in neonates with acute respiratory distress syndrome(ARDS).Methods:The data of 30 neonates with ARDS who needed mechanical ventilation in neonatal intensive care unit of Xi′an Children′s Hospital from January 2016 to November 2018 were collected as observation group, including 12 cases in mild group, 10 cases in moderate group and 8 cases in severe group.The data of healthy newborns during the same period were taken as control group.The serum levels of CC16 and SP-A were detected by ELISA.The serum levels of CC16 and SP-A among different groups were compared.Results:The levels of serum CC16 and SP-A in ARDS group were (59.35±3.67)mg/L and(75.38±6.27)mg/L respectively, (11.26±1.32)mg/L and(18.15±2.69)mg/L in healthy group.The difference was significant( P<0.05). And the differences of serum CC16 and SP-A levels among different degree ARDS groups were significant( P<0.05). The levels of serum CC16 in mild, moderate and severe subgroup were(38.27±16.01)mg/L, (51.25±15.63)mg/L, (84.76±13.12)mg/L and SP-A were(47.02±7.18)mg/L, (73.12±7.98)mg/L, (96.45±12.50)mg/L, which increased with disease severity. Conclusion:Serum CC16 and SP-A are increased and correlated with the severity of neonatal ARDS, which may be used as the index for evaluating the severity of neonatal ARDS in the future.
